908 Devices Inc. (Nasdaq: MASS) reported its financial results for the first quarter of 2025, showing a significant increase in revenue from continuing operations, which grew 59% compared to the prior year. This growth was primarily driven by an increase in product and service revenue. The company's net income attributable to common stockholders reached $43.6 million for the first quarter, a notable improvement from a net loss of $10.9 million in the corresponding prior year period. This increase in net income was largely influenced by a $56.6 million gain from the divestiture of its bioprocessing product portfolio, despite a loss from discontinued operations during the first two months of the quarter. Operating expenses rose to $16.6 million, up from $11.5 million in the previous year, influenced by a $2.5 million non-cash charge related to the change in fair value of contingent consideration liability and expenses from the RedWave Technology acquisition. The adjusted EBITDA showed a loss of $4.6 million, an improvement from a $5.3 million loss in the same period last year. The company holds cash, cash equivalents, and marketable securities totaling $124.3 million as of March 31, 2025, with no outstanding debt. For the full year 2025, 908 Devices maintains its revenue guidance from continuing operations at $53 million to $55 million, representing an 11% to 15% growth compared to 2024.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。